Remdesivir News and Research

RSS

Antidepressant fluoxetine (Prozac) suppresses replication of SARS-CoV-2

A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.

16 Jun 2020

Experimental drug to prevent deadly blood coagulation in patients with COVID-19

The British Heart Foundation is funding a trial for an experimental drug that could prevent the life-threatening blood clots that are seen in the lungs of the patients with COVID-19 or those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug named TRV027 is said to normalize the hormonal imbalance that can be seen in patients developing COVID-19, experts said.

15 Jun 2020

Combination of nelfinar and amodiaquine shows promise for treating COVID-19

Six months into the COVID-19 pandemic, more than 7.4 million people have been infected, and more than 410 000 have died. As yet, there is no treatment or vaccine for the disease.

15 Jun 2020

A teen’s death from COVID

It started as a normal day. Dawn Guest, 54, got up and headed out to her job as a nurse around 5 a.m. She heard her 16-year-old son, Andre, stirring in his room, but he had always been an earlier riser, even when his school was shut for COVID-19.

15 Jun 2020

Remdesivir prevents replication of SARS-CoV-2 in human intestinal organoids

A new German study published on the preprint server bioRxiv* in June 2020 shows that the drug remdesivir can reduce the replication of SARS-CoV-2 in human intestinal organoids.

14 Jun 2020

A family with five doctors — and two COVID deaths

On the morning of April 1, Dr. Priya Khanna inched her way from the bedroom to the front door, using walls, doors and railings to hold herself up long enough to get to the stretcher waiting outside. She had been battling COVID-19 for five days and was struggling to breathe.

11 Jun 2020

Tocilizumab in Critical COVID-19 Patients

A new study by scientists at Metro Infectious Disease Consultants and published on the preprint server medRxiv* in June 2020 reports that the cytokine blocker tocilizumab is a useful adjunct to supportive medical care in severe COVID-19, with increased survival and a lower requirement for mechanical ventilation.

10 Jun 2020

Immuno-oncology may accelerate the development of treatments for COVID-19

Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.

10 Jun 2020

Protease inhibition could help defeat SARS-CoV-2

As the COVID-19 pandemic caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread around the world, many researchers are studying epidemiological models to predict its propagation. As of yet, there are no effective vaccines that could counter the SARS- CoV-2 infection or drugs to treat COVID-19 disease

9 Jun 2020

Kidney enzyme renalase a potential therapy for severe COVID-19

Researchers from Yale School of Medicine have discovered that a low blood level of an enzyme called renalase is associated with severe coronavirus disease 2019 (COVID-19).

7 Jun 2020

Assessing the integrity of remdesivir clinical trial during COVID-19 pandemic

As acknowledged in the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19 recently published in Lancet (Wang, et al., April 29, 2020), a statistician at Rutgers Cancer Institute of New Jersey was called on to guard the integrity of that trial.

4 Jun 2020

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

Convalescent plasma therapy improves outcomes in majority of COVID-19 patients

First peer-reviewed publication on US trial results from Houston Methodist published in The American Journal of Pathology

3 Jun 2020

A cytokine pattern that predicts adverse outcomes in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports the discovery of a predictive pattern of cytokines in COVID-19 infection that could guide clinical management if validated.

2 Jun 2020

Crucial ingredient from University of Kansas included in authorized COVID-19 drug

When the Food and Drug Administration issued an emergency-use authorization for the investigational pharmaceutical remdesivir to treat COVID-19 on May 1, in part it was due to pioneering work performed by pharmaceutical chemists at the University of Kansas School of Pharmacy in 1990.

1 Jun 2020